Please ensure Javascript is enabled for purposes of website accessibility

Instant Double Aftermath: Is InterMune Inc. In Play?

By Dave Williamson – Feb 27, 2014 at 10:08PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

After InterMune's instant double this week and killer phase 3 results, the company may be a takeover target. So, who do we think is buying?

While InterMune (ITMN.DL) was technically a loser today after falling 3%, this can only be seen as natural profit-taking after the stock detonated upward 170% in a single day earlier this week. The company has a first-in-class idiopathic pulmonary fibrosis drug that just aced its phase 3 trial and has solid market potential, possibly up to half a billion dollars in annual sales.

This being InterMune's only drug, Motley Fool health-care analyst David Williamson says in the following video that he agrees with analysts that this now looks like a takeover target. In the video, David looks ahead to the FDA approval process and discusses InterMune's chances of a favorable ruling, and discusses which companies would make the most likely suitors. This will definitely be a story to watch this year.

David Williamson has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Stocks Mentioned

Sanofi Stock Quote
Sanofi
SNY
$45.01 (-1.88%) $0.86
InterMune, Inc. Stock Quote
InterMune, Inc.
ITMN.DL
GSK plc Stock Quote
GSK plc
GSK
$35.35 (0.91%) $0.32
Gilead Sciences Stock Quote
Gilead Sciences
GILD
$89.03 (1.29%) $1.13

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.